SMMT
USDSummit Therapeutics Inc. Common Stock
Preço em tempo real
Gráfico de preços
Métricas-chave
Métricas de mercado
Abertura
$17.780
Máximo
$18.120
Mínimo
$17.370
Volume
2.88M
Fundamentos da empresa
Capitalização de mercado
13.0B
Setor
Biotecnologia
País
United States
Estatísticas de negociação
Volume médio
4.10M
Bolsa de valores
NGM
Moeda
USD
Faixa de 52 semanas
Notícias relacionadas
Summit Therapeutics to Present at Upcoming Investor Conferences
Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at four upcoming investor conferences during the remainder of this year. Members of the
Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025
Conducted by Akeso, HARMONi-A Represents the First Statistically Significant OS Benefit Achieved in a Phase III Study by an Ivonescimab-Containing Regimen Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the
Guggenheim Reiterates Buy on Summit Therapeutics, Maintains $40 Price Target
Guggenheim analyst Brad Canino reiterates Summit Therapeutics with a Buy and maintains $40 price target.
Summit Therapeutics Raises $500 Million in Private Placement
Fundraise Led by Leading Biopharma Institutional Investors & Insiders $500 Million in Gross & Net Proceeds Raised at Yesterday's Closing Price of $18.74 Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit,"
Barclays Maintains Underweight on Summit Therapeutics, Raises Price Target to $16
Barclays analyst Etzer Darout maintains Summit Therapeutics with a Underweight and raises the price target from $13 to $16.
HC Wainwright & Co. Maintains Buy on Summit Therapeutics, Lowers Price Target to $40
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Summit Therapeutics with a Buy and lowers the price target from $50 to $40.
Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025
Conference Call to be Held at 8:00am ET Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") will host an ESMO Data Update and Third Quarter Earnings Call on Monday, October 20, 2025, before the
Ações relacionadas
Mantenha-se atualizado
Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.